Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a primary diagnosis of single or recurrent MDD, diagnosed according to DSM-5®. The current MDE must be confirmed using the Mini International Neuropsychiatric Interview (MINI).~* The patient has a MADRS total score ≥24 at screening and baseline.~* The patient has had the current MDE for ≥3 months and \< 12 months.~* The patient has been treated with an SSRI as monotherapy (citalopram, escitalopram, paroxetine, sertraline) for at least 6 weeks at licensed dose for the current MDE with a partial response and is a candidate for a switch in the investigator's opinion.~* The patient wants to switch antidepressant treatment.~Exclusion Criteria:~* The patient has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.~Other in- and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Type: EXPERIMENTAL): 8 weeks treatment
- Desvenlafaxine (Type: ACTIVE_COMPARATOR): 8 weeks treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).